Since 2016, Docter, along with its subsidiary, Horn Enterprise, has been developing a non-invasive blood sugar trend monitoring technology, alleviating the necessity for blood sampling.
The news follows an October announcement that the parties upsized a PIPE on the deal by $75 million and secured a $178 million backstop against redemptions.